Negocios · 15/4/20111 min de lectura
Determination of Regulatory Review Period for Purposes of Patent Extension; ATRYN; Correction
Traducción automática local · Idioma original de la fuente
Resumen
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of March 21, 2011 (76 FR 15323). The document announced the determination of the regulatory review period for ATRYN. The document was published with an incorrect docket number. This document corrects that error.